Document Detail


Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa.
MedLine Citation:
PMID:  12809998     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Patients with Parkinson's disease (PD) have an increased risk of falling that has yet to be fully explained. To better understand the gait disturbance in PD and the factors that contribute to falls, we quantitatively evaluated: (1) the relationship between gait variability (a marker of fall risk in other populations), fall history, and other parkinsonian features, and (2) the effects of levodopa on these relationships. METHODS: The average stride time and stride-to-stride variability were measured using force-sensitive insoles during comfortable walking. Fall frequency, motor control, function, and mental health were measured using the Unified Parkinson's Disease Rating Scale (UPDRS), the Mini-Mental State Exam (MMSE), and the timed motor tests of the Core Assessment Program for Intracerebral Transplantations (CAPIT) in 32 subjects with idiopathic PD, in an "off" (unmedicated) state and again in an "on" (medicated) state. RESULTS: Average stride time was not associated with any UPDRS or CAPIT measure and was similar in fallers and non-fallers in "off" and "on" states (p>0.27). Stride time variability was significantly associated with fall frequency as well as with total scores on the CAPIT and the UPDRS, ADL abilities, and motor function. Stride time variability and falls were not related to tremor, rigidity or bradykinesia in the "off" state. 41% of subjects reported one or more falls. Stride time variability was 8.8+/-7.9% in fallers and 4.2+/-1.3% in non-fallers (p<0.009). Stride time variability significantly improved in response to levodopa, both in fallers and non-fallers, but remained increased in fallers (vs. non-fallers). CONCLUSIONS: The patho-physiology responsible for impaired stride-to-stride regulation of gait timing is apparently independent of other cardinal features of PD, i.e., tremor, rigidity, or bradykinesia, but is responsive to levodopa. Stride-to-stride variability is especially impaired among PD subjects with a history of falls, suggesting, for the first time, the possibility of exaggerated impairment of internal clock function in PD fallers.
Authors:
Joanna D Schaafsma; Nir Giladi; Yacov Balash; Anna L Bartels; Tanya Gurevich; Jeffrey M Hausdorff
Related Documents :
18651368 - Reliability of the vmaxst portable metabolic measurement system.
16096818 - Role of hypokinesia and bradykinesia in gait disturbances in huntington's disease: a bi...
20467528 - The effects of a twelve-week home walking program on cardiovascular parameters and fati...
19848558 - Physiological cost of walking in those with chronic fatigue syndrome (cfs): a case-cont...
8226468 - Respiratory load compensation. ii. role of the cerebellum.
7167828 - Trunk asymmetries in a belgian school population.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of the neurological sciences     Volume:  212     ISSN:  0022-510X     ISO Abbreviation:  J. Neurol. Sci.     Publication Date:  2003 Aug 
Date Detail:
Created Date:  2003-06-17     Completed Date:  2003-08-14     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0375403     Medline TA:  J Neurol Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  47-53     Citation Subset:  IM    
Affiliation:
Movement Disorders Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv University, 6 Weizmann Street, Tel Aviv 64239, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Activities of Daily Living
Aged
Aged, 80 and over
Antiparkinson Agents / therapeutic use*
Female
Gait / physiology*
Gait Disorders, Neurologic / drug therapy,  physiopathology
Humans
Levodopa / therapeutic use*
Male
Middle Aged
Neurologic Examination
Parkinson Disease / drug therapy*,  physiopathology*
Psychiatric Status Rating Scales
Reference Values
Risk Factors
Time Factors
Grant Support
ID/Acronym/Agency:
AG-08812/AG/NIA NIH HHS; AG-14100/AG/NIA NIH HHS; HD-39838/HD/NICHD NIH HHS; RR-13622/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Antiparkinson Agents; 0/Levodopa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Early pregnancy factor treatment suppresses the inflammatory response and adhesion molecule expressi...
Next Document:  Coagulation-fibrinolysis abnormalities in patients receiving antiparkinsonian agents.